Home | Welcome to Contract Pharma   
Last Updated Saturday, October 25 2014
Print

Financial Report: AMRI 3Q



Published November 6, 2012
Related Searches: Manufacturing Development
AMRI

3Q Revenues: $55.8 million (+11%)
 
3Q Loss: $2.1 million (loss of $5.9 million 3Q11)
 
YTD Revenues: $159.5 million (-1%)
 
YTD Loss:
$5.7 million (loss of $7.9 million YTD11)
 
Comments:
Total contract revenue for the quarter was $45.6 million, up 4%. Large Scale manufacturing revenue was $29.3 million (+14%). Discovery Services revenue was flat at $8.9 million. Development/Small-Scale Manufacturing revenue was $7.4 million (-20%). Royalty revenue in the quarter was $9.4 million (+45%) related to worldwide sales of Allegra, and certain generic forms of Allegra. Revenue in the quarter includes milestones totaling $0.8 million from the company’s 2005 licensing agreement with BMS.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On